Realtime | Geld | Brief | Zeit |
---|---|---|---|
8,500 | 9,360 | 20:43 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
18.09. | Selvita pharma sees market stabilising; end-2025 and contract renewals crucial for 2026 backlog | 1 | PAP | ||
SELVITA Aktie jetzt für 0€ handeln | |||||
18.09. | Selvita pharma backlog for 2025 amounts to PLN 334 mln, up 6 pct y/y | 1 | PAP | ||
18.09. | Selvita pharma posts PLN 4.6 mln attributable net loss in Q2 '25, above expectations | 1 | PAP | ||
27.03. | Selvita S.A.: Selvita Reports Rebound in H2 2024 and 11% Increase in Backlog for 2025 | 370 | PR Newswire | KRAKOW, Poland, March 27, 2025 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of Europe's leading preclinical CROs, has announced its financial results for 2024... ► Artikel lesen | |
21.11.24 | Selvita Reports Significant Recovery in H2 2024, Sees Promising Outlook for the Future | 232 | PR Newswire | KRAKÓW, Poland, Nov. 21, 2024 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading preclinical contract research organizations in Europe, has published... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,765 | +1,52 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
PALATIN TECHNOLOGIES | - | - | PALATIN TECHNOLOGIES INC - S-1/A, General form for registration of securities | ||
COSCIENS BIOPHARMA | 2,040 | -3,77 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
HALOZYME THERAPEUTICS | 56,06 | -1,09 % | Halozyme Therapeutics, Inc.: Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s | Royalty revenue contribution expected to begin as early as 2030
Initial partner targets include derisked MoAs that are approved blockbusters today
Highly scalable... ► Artikel lesen | |
AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
ABCELLERA BIOLOGICS | 5,462 | +10,37 % | Why Did AbCellera's Stock Jump Over 7% After Hours? | ||
BIOMERIEUX | 113,70 | -1,04 % | Dividendenbekanntmachungen (09.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALLSTATE CORPORATION US0200021014 1 USD 0,8776 EUR ALPHABET INC CL A US02079K3059 0,21 USD 0,1842 EUR ALPHABET INC CL C US02079K1079 0... ► Artikel lesen | |
GLOW LIFETECH | 0,026 | 0,00 % | Glow Lifetech to Present at the Annual Smallcap Discoveries Conference in Vancouver | Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce the company is participating in... ► Artikel lesen | |
BIO-RAD LABORATORIES | 260,10 | +2,20 % | Disruption! Ab jetzt wird alles anders: BioNxt Solutions, BioNTech, Bio-Rad Laboratories | Der Ausbruch der Corona-Pandemie hat vieles verändert. Frei nach dem Motto "Einfach mal machen" setzten Unternehmen wie BioNTech auf die mRNA-Technologie. Der Erfolg inklusive Milliardenumsätzen folgte... ► Artikel lesen | |
AVID BIOSERVICES | 12,100 | 0,00 % | Avid Bioservices Appoints Kenneth Bilenberg as CEO | ||
BIOLINERX | 3,570 | +6,25 % | XFRA YP2: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
WHITEHAWK THERAPEUTICS | 1,790 | -5,29 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | MORRISTOWN, N.J., Aug. 7, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to... ► Artikel lesen | |
MINERVA NEUROSCIENCES | 2,460 | +32,97 % | Minerva Neurosciences, Inc: Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results | FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia
Evaluation of strategic alternatives
BURLINGTON, Mass., Aug. 14, 2025(Nasdaq:... ► Artikel lesen | |
OVID THERAPEUTICS | 1,420 | -1,39 % | Ovid Therapeutics Inc.: Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds | NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant... ► Artikel lesen |